THE MOLECULAR MECHANISM OF FASL-MEDIATED CYTOXICITY BY CD4(+) TH1 CLONES


ELKHATIB M., STANGER B., DOGAN H. H. , CUI H., JU S.

CELLULAR IMMUNOLOGY, vol.163, no.2, pp.237-244, 1995 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 163 Issue: 2
  • Publication Date: 1995
  • Doi Number: 10.1006/cimm.1995.1122
  • Title of Journal : CELLULAR IMMUNOLOGY
  • Page Numbers: pp.237-244

Abstract

Murine CD4(+) Th1 clones require de novo synthesis of proteins to express a cytotoxicity that is mediated by de novo synthesized Fas ligand (FasL). The cytotoxic process of the CD4(+) Th1 effecters can be separated into four stages, namely conjugate formation, activation, lethal hit, and effector-independent target cell death. The present study describes the cytotoxic process in terms of FasL induction and Fas/FasL molecular interactions for death signal transduction. Fas-Ig fusion proteins, cycloheximide, actinomycin D, and EGTA + MgCl2 were used to analyze each stage of the cytotoxic process in terms of FasL/Fas participation. The results demonstrate that the activation-induced de novo mRNA and protein synthesis were for FasL, which provided the predominant cytotoxic activity of CD4(+) Th1 effecters. Once activated, Th1 effecters express cytotoxic activity in the presence of EGTA + MgCl2, an experimental [Ca2+](ext)-independent condition characteristic of FasL-mediated cytotoxicity. The ability of Fas-Ig to inhibit target lysis declined rapidly after conjugate formation, indicating that Fast-mediated lethal hit is critically dependent on conjugate formation and, once delivered, the effector-independent target lysis proceeds. After the lethal hit stage, transduction of Fas-mediated death signal was independent of de novo synthesis of macromolecules in targets because treatments that inhibited more than 98% of the macromolecule synthesis had little effect on target lysis. Our study provides the first molecular view in terms of FasL/Fas of the cytotoxic process of CD+ Th1 cells. (C) 1995 Academic Press, Inc.